Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Orexigen
Orexigen
Orexigen Approval Shows That Diversification Strategy Can Work
Seeking Alpha
Thu, 12/9/10 - 10:55 am
Orexigen
FDA
Contrave
Diet Drug Rally: Orexigen, Vivus, Arena
TheStreet.com
Wed, 12/8/10 - 12:27 pm
obesity
Orexigen
Vivus
Arena Pharmaceuticals
Contrave
Qnexa
Orexigen Wins U.S. Panel’s Backing for New Diet Pill
Bloomberg Businessweek
Tue, 12/7/10 - 06:05 pm
obesity
Orexigen
advisory panels
FDA
Contrave
Orexigen Therapeutics: FDA Panel Live Blog
TheStreet.com
Tue, 12/7/10 - 07:56 am
FDA
advisory panels
Orexigen
Contrave
obesity
Orexigen braces for advisory panel's Contrave review
Fierce Biotech
Mon, 12/6/10 - 05:04 pm
Orexigen
Contrave
FDA
advisory panels
obesity
Advisory Votes Against Expanding Use of GSK’s, Merck’s Prostate Drugs: Biotech's Latest Tribulations
Seeking Alpha
Sun, 12/5/10 - 11:52 am
GSK
Merck
Avodart
enlarged prostate
prostate cancer
Proscar
Orexigen
obesity
Contrave
Novartis
JNJ
Merck KGaA
FDA: Proposed Weight Loss Drug Contrave Raises Blood Pressure
WSJ Online
Fri, 12/3/10 - 11:06 am
FDA
obesity
Contrave
hypertension
Orexigen
Orexigen's Diet Pill Has Unclear Benefits, an FDA Staff Review Indicates
Bloomberg
Fri, 12/3/10 - 08:46 am
Orexigen
FDA
Contrave
obesity
Orexigen: Don't Count Contrave Out Yet
Seeking Alpha
Fri, 12/3/10 - 06:45 am
FDA
obesity
Orexigen
Contrave
Arena Pharmaceuticals
Vivus
Orexigen Options Suggest Contrave Diet Pill May Avoid Arena, Vivus Delays
Bloomberg
Thu, 12/2/10 - 10:17 am
Orexigen
options
Contrave
obesity
Vivus
Arena Pharmaceuticals
Biotech Calendar: Key Dates for December
TheStreet.com
Tue, 11/30/10 - 09:20 am
Delcath
Arena Pharmaceuticals
RXi Pharmaceuticals
Cell Therapeutics
Amgen
Incyte
Celgene
Corcept Therapeutics
Affymax
Targacept
Exelixis
Orexigen
ONYX Pharmaceuticals
Seattle Genetics
MannKind
Alimera
AstraZeneca
Human Genome Sciences
Orexigen: Contrave FDA Panel Preview
TheStreet.com
Tue, 11/30/10 - 08:02 am
FDA
advisory panels
Orexigen
Contrave
obesity
Arena Pharmaceuticals
Vivus
Long Odds Seen For Diet Drugs
WSJ Online
Tue, 10/26/10 - 12:37 pm
obesity
Arena Pharmaceuticals
Eisai
Orexigen
Contrave
FDA's Top Q4 Blockbuster Drug Decisions
Fierce Biotech
Tue, 10/12/10 - 11:26 am
Linjeta
Biodel
Afrezza
MannKind
FDA
Benlysta
Human Genome
GSK
Bydureon
Eli Lilly
Amylin
Alkermes
Brilinta
AstraZeneca
Pradaxa
Boehringer Ingelheim
Qnexa
Vivus
Contrave
Orexigen
ipilimumab
Bristol-Myers Squibb
Merck KGaA
cladribine
With Meridia Gone, Can’t We Just Admit There’s No Money in Diet Drugs?
BNET Pharma
Mon, 10/11/10 - 05:55 pm
Meridia
diet drugs
Abbott Laboratories
GSK
Roche
Allergan
Novo Nordisk
Sanofi
Merck
Eli Lilly
Amylin
Takeda
Orexigen
Orexigen Shares Popped: What You Need to Know
Motley Fool
Thu, 10/7/10 - 06:04 pm
Orexigen
obesity
Arena Pharmaceuticals
Vivus
Vivus Races to Capture U.S. Approval of Obesity Drug
Seeking Alpha
Mon, 09/27/10 - 10:43 am
obesity
Vivus
Qnexa
Orexigen
Contrave
Arena Pharmaceuticals
Biotech Investor Calendar: Obesity Drugs
TheStreet.com
Tue, 09/21/10 - 12:10 pm
Vivus
Qnexa
Orexigen
obesity
Contrave
Arena Pharmaceuticals
Arena Pharma: FDA Panel Live Blog
TheStreet.com
Thu, 09/16/10 - 12:18 pm
FDA
advisory panels
Arena Pharmaceuticals
obesity
Orexigen
Abbott Laboratories
Contrave
Meridia
Speculative Bubble Growing Around Diet Drugs
BNET Pharma
Tue, 09/14/10 - 05:42 pm
Arena Pharmaceuticals
obesity
Takeda
Orexigen
Contrave
Abbott Laboratories
Meridia
Qnexa
Vivus
Pages
« first
‹ previous
…
9
10
11
12
13
14
15
16
17
next ›
last »